. home.aspx



BMS’ Opdivo disappoints in late-stage trial

June 26, 2019 / Anna Smith

Bristol-Myers Squibb has announced topline results from its CheckMate -459 trial evaluating Opdivo (nivolumab) in patients with unresectable hepatocellular carcinoma (HCC). The results show that the cancer drug failed to show superiority to Nexavar (sorafenib), and did not achieve statistical significance for its primary endpoint of overall survival. The news isn’t all negative, however, as a clear trend was demonstrated towards improvement in overall survival for patients treated with Opdivo compared Nexavar. The drug is currently being studied by the company across multiple settings and lines of therapy for HCC, including as monotherapy in the adjuvant setting and in combination with Yervoy (ipilimumab) for previously treated patients. The company say that they are still “encouraged by the promising efficacy and safety trends seen with Opdivo in CheckMate -459, especially as HCC is a devastating and difficult-to-treat cancer, for which there have been no significant advan...